News and Information

News 2018-05-04T03:12:28+00:00

Bonti Announces Start of LANTERN-2 Phase 2 Clinical Trial Evaluating EB-001T in Treating Focal Muscle Pain

Follows Completion of LANTERN-1 Clinical Trial Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced it has initiated dosing in its LANTERN-2 clinical trial, a Phase 2 clinical trial under Bonti’s LANTERN (Long-Acting NeuroToxin-E Relief, Non-opioid) clinical program aimed at treating focal muscle [...]

May 9th, 2018|Categories: Press Releases|

Bonti Announces Scientific Presentation at Premier Aesthetic Plastic Surgery Conference

EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018 Bonti, Inc., an innovative clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin products for therapeutic and aesthetic applications, today announced a Hot Topics presentation for its therapeutic product candidate, EB-001T, and for its aesthetic product candidate, EB-001A, at the American Society for Aesthetic Plastic [...]

April 25th, 2018|Categories: Press Releases|

Bonti Appoints Dr. Jacob Chacko to Board of Directors

Bonti, a privately-held, clinical-stage biotechnology company, today announced the appointment of Dr. Jacob Chacko to its Board of Directors, effective immediately. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. (NASDAQ: RXDX) since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications, Facility Operations, and IT, and has helped lead over $500 [...]

February 12th, 2018|Categories: Press Releases|

Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction

Bonti, a privately-held, clinical-stage biotechnology company, today announced the initiation of the SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. The first clinical study, SHINE-1, is a randomized, placebo-controlled, double-blind, parallel arm trial to evaluate the safety and efficacy of EB-001 injections in patients undergoing Mohs micrographic surgery on the forehead. [...]

February 8th, 2018|Categories: Press Releases|

Bonti Announces Close of $15.5 Million Series C Funding and Appointment of David Ramsay as Chief Financial Officer

Latest Financing to Enable Continued Clinical Development of Lead Product EB-001 to Treat Musculoskeletal Pain Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully closed a $15.5 million Series C financing, bringing the cumulative investment in the Company to over $36 million. Capital from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its [...]

January 23rd, 2018|Categories: Press Releases|

Bonti to Present at Two Prestigious Healthcare Conferences

Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco Bonti, a privately-held, clinical-stage biotechnology company, today announced that Fauad Hasan, CEO and co-founder, will present at the following in San Francisco the same week as the 36th Annual J.P. Morgan Healthcare Conference: The Neuroscience Innovation Forum on Sunday, January 7th at 1:50 PM (PT) The 5th Annual [...]

January 5th, 2018|Categories: Press Releases|